Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 19;10:3236. doi: 10.1038/s41467-019-11137-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Ab-retargeting inhibits the growth of subcutaneous and disseminated tumors in Ad5-vaccinated mice. a Illustration showing the experimental time course of tumor establishement in Ad5-immunized or Ad5-naive mice by s.c. injection of PolySia-expressing tumor cells (MC38-pSia, ‚CMT-pSia, or B16F10-pSia as indicated in the Fig. 2b–d) and subsequent treatments with purified DE1scFv-pSia, or saline, respectively. b MC38-pSia tumors were established in Ad5-naive mice (upper panel) or Ad5-immunized mice (lower panel), and treated with DE1scFv-pSia or saline (control). Tumor development (left panel) and survival (right panel) were monitored. Group size: Ad5-naive control, n = 7; Ad5-naive DE1scFv-pSia treated, n = 8; Ad5-immunized control, n = 8; Ad5-immunized DE1scFv-pSia treated, n = 9. Median survival (ms) in days for Ad5-naive control: 30; Ad5-naive DE1scFv-pSia treated: 24; Ad5-immunized control: 21; Ad5-immunized DE1scFv-pSia treated: 26. c Tumor development (left panel) and survival (right panel) were monitored in Ad5-immunized mice bearing CMT-pSia tumors. Group size: n = 8; ms control: 23; ms DE1scFv-pSia: 31. d Tumor development (left panel) and survival (right panel) were monitored in Ad5-immunized mice B16F10-pSia tumor-bearing mice. Group size: n = 5; ms control: 17; ms DE1scFv-pSia: 24. e According to the shown treatment scheme, Ad5-immunized mice were injected i.v. with the lung adenocarcinoma cell line CMT-pSia to establish lung colonies. Mice were then treated i.v. with purified DE1scFv-pSia at the indicated time points or received saline as control. f Representative H/E-stained lung sections of control and DE1scFv-pSia treated individuals at endpoint examination (day 17). g Tumor burden in the lung was calculated based on microscopic investigations of H/E-stained lung sections (n = 4). Log-rank (Mantel–Cox) test was used to calculate survival in b, c, and d and two-tailed unpaired t test was used to calculate statistics in g: *p ≤ 0.05; **p ≤ 0.01, ***p ≤ 0.001. Error bars refer to standard deviation (SD). Source data are provided as a source data file